**Background of FRAT1 Antibody**
The FRAT1 (Frequently Rearranged in Advanced T-cell lymphomas 1) gene, also known as GSK-3β-interacting protein, encodes a protein that plays a critical role in the Wnt/β-catenin signaling pathway. Initially identified due to its frequent rearrangement in T-cell lymphomas, FRAT1 functions as a positive regulator of Wnt signaling by binding to glycogen synthase kinase-3β (GSK-3β). This interaction prevents GSK-3β from forming a degradation complex with β-catenin, thereby stabilizing β-catenin and promoting its nuclear translocation to activate target genes involved in cell proliferation, differentiation, and oncogenesis.
FRAT1 antibodies are essential tools for detecting and studying the expression, localization, and function of FRAT1 in both normal and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to investigate FRAT1's role in cancers, particularly those with dysregulated Wnt signaling, such as colorectal, hepatocellular, and breast carcinomas. Additionally, these antibodies aid in exploring FRAT1's involvement in developmental processes and stem cell regulation. Studies also link aberrant FRAT1 expression to chemoresistance and poor prognosis, highlighting its potential as a therapeutic target. Researchers rely on FRAT1 antibodies to dissect molecular mechanisms in disease models and validate experimental findings in clinical samples.